Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315235 | 0.85 | AGTR1 (0.53) | KDM4EGLAAGTR1MEN1KMT2A | |
| SCHEMBL5392212 | 0.84 | KDM4E (0.58) | KDM4EGLAAGTR1MEN1KMT2A | |
| SCHEMBL8602088 | 0.84 | AGTR1 (0.55) | KDM4EGLAAGTR1MEN1KMT2A | |
| SCHEMBL9279236 | 0.83 | ALDH1A1 (0.71) | KDM4EGLAAGTR1KMT2AALDH1A1 | |
| SCHEMBL8943473 | 0.82 | AGTR1 (0.57) | KDM4EAGTR1MEN1KMT2AALDH1A1 | |
| SCHEMBL21501690 | 0.81 | KDM4E (0.56) | KDM4EGLAKMT2AALDH1A1HPGD | |
| SCHEMBL8691774 | 0.81 | AGTR1 (0.52) | KDM4EGLAAGTR1MEN1KMT2A | |
| SCHEMBL21532107 | 0.81 | AGTR1 (0.49) | KDM4EGLAAGTR1MEN1KMT2A | |
| SCHEMBL5387032 | 0.81 | SIRT2 (0.63) | KDM4EAGTR1MEN1KMT2AALDH1A1 | |
| SCHEMBL14577687 | 0.81 | TSHR (0.53) | KDM4EGLAAGTR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021188880-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20080229520-A1 | Hair Colorants with Indigoid Vat Dyes | WELLA AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KDM4E 4108/4885GLA 2469/4885AGTR1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.